SL-172154: Brief Review of its R&D Progress and the Clinical Result in 2023 ASH

14 November 2023
5 min read

In 2023 ASH, the safety, pharmacodynamic, and anti-tumor activity of SL-172154 as monotherapy and in combination with Azacitidine (AZA) in relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) patients (pts) will be reported orally.

SL-172154's R&D Progress

The drug SL-172154 is a fusion protein that targets CD40 and CD47. Fusion proteins are a type of therapeutic agent that combines two or more proteins to create a new molecule with enhanced therapeutic properties. The therapeutic areas targeted by SL-172154 include neoplasms (abnormal growth of cells), digestive system disorders, endocrinology and metabolic diseases, hemic and lymphatic diseases, and urogenital diseases. 

Currently, the drug is in Phase 1 of clinical development, which means it is being tested in a small group of patients to evaluate its safety and dosage. And the clinical trial areas for SL-172154 are primarily in the United States, United Kingdom, and Canada. The key indication is Acute Myeloid Leukemia and Myelodysplastic Syndromes. .

Detailed Clinical Outcome of SL-172154

The objectives of this dose escalation cohorts include evaluation of safety, dose-limiting toxicity (DLT), recommended phase 2 dose, pharmacokinetic and pharmacodynamic effects and efficacy per IWG 2006 for MDS and ELN 2017 for AML.

In this study, SL-172154 was administered IV weekly of a 28-day cycle as monotherapy or with AZA 75 mg/m2 for 7 days per cycle. mTPI-2 was used for dose escalation with a DLT threshold of 20%. Pts  18 years old with R/R HR-MDS or R/R AML were eligible for dose escalation cohorts. In addition, UnTx pts with TP53 mutant (TP53m)-MDS were eligible for SL-AZA cohorts.

The result showed that Infusion-related reactions (IRRs) were the most common SL-172154-related treatment-emergent AEs (TEAEs) reported in 13 (68%) and 8 (44%) pts in SL-mono and SL-AZA cohorts, respectively. IRRs (51 events) were Grade (G) 1 or 2 except for 3 G3 events (1 each at 6 mg/kg SL-mono and SL-AZA; 1 at 3 mg/kg SL-mono). Other SL-172154-related TEAEs observed in  3 pts were AST increased (4; 21%), ALT increased (3; 16%) and nausea (3; 17%) in SL-mono cohorts, and nausea (3; 17%) in SL-AZA cohorts. All events of AST/ALT increased were transient. Only one DLT (G3 IRR in the 6 mg/kg SL-AZA cohort) was reported, which required a dose reduction to 3 mg/kg. As of July 10, 2023, in SL-mono cohorts, 1 pt with R/R AML post 7+3, FLAG and VEN/AZA achieved Morphologic Leukemia-Free State (blast reduction from 19% to <5%) after 1 cycle of 6 mg/kg SL-172154. In 12 evaluable pts with R/R AML receiving SL-AZA, although no objective responses (OR) were observed, relative reduction in bone marrow (BM) blasts from baseline was reported in 2/5 pts at 1 mg SL-AZA (-50%, -75%) and 5/7 pts at 3 mg SL-AZA (ranging from -35% to -90%). SL-172154 induced elevations in serum IL-12p40, IP-10, IL-8, IL-10, MIP3α and MCP1: greater response at 3 mg/kg compared to 1 mg/kg while similar between 3 and 6 mg/kg. 

It can be concluded that SL-172154 was well tolerated up to 3 mg/kg as monotherapy and in combination with AZA. Preliminary efficacy signals were detected in UnTx TP53m-MDS and R/R AML. A response to SL-172154 monotherapy, dose-dependent increases in serum cytokines and accumulation of mature myeloid cells in BM suggest a potential role for CD40 stimulation. Based on the safety, preliminary efficacy and pharmacodynamic activity, 3 mg/kg SL-172154+ AZA is being evaluated in treatment naïve pts with TP53m AML and HR-MDS.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

图形用户界面, 应用程序, Teams

描述已自动生成

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

图形用户界面, 应用程序, Teams

描述已自动生成

图形用户界面, 应用程序

中度可信度描述已自动生成

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

图形用户界面, 应用程序

描述已自动生成

Click on the image below to embark on a brand new journey of drug discovery!

Pfizer, Sosei Heptares’ collaborator, moves forward with the Phase 1 trial of its GLP-1 receptor agonist PF-06954522
Latest Hotspot
3 min read
Pfizer, Sosei Heptares’ collaborator, moves forward with the Phase 1 trial of its GLP-1 receptor agonist PF-06954522
14 November 2023
Pfizer informed Sosei Group Corporation about initiating a Phase 1 clinical trial with a new oral GLP-1 receptor agonist, PF-06954522, discovered in a joint research venture. Sosei Heptares' StaR® technology was used in the process.
Read →
What are ATR inhibitors and how do you quickly get the latest development progress?
What are ATR inhibitors and how do you quickly get the latest development progress?
14 November 2023
ATR, a core DDR kinase, senses replication stress and signals S and G2/M checkpoints to initiate DNA repair. It's a hot target in anti-cancer drug development, with some ATR inhibitors already in clinical trials.
Read →
Nivolumab: brief review of its R&D progress and the clinical result in 2023 ASCO
Nivolumab: brief review of its R&D progress and the clinical result in 2023 ASCO
14 November 2023
Recently the clinical trial of Nivolumab, a PD-1 blockade, for the treatment of RR HL was reported at the ASCO Congress.
Read →
TILT Biotherapeutics reports encouraging clinical results for primary resource TILT-123 at 2023 Cancer Immunotherapy Society
Latest Hotspot
3 min read
TILT Biotherapeutics reports encouraging clinical results for primary resource TILT-123 at 2023 Cancer Immunotherapy Society
14 November 2023
At the 2023 Society for Immunotherapy of Cancer meeting, TILT Biotherapeutics revealed Phase I results for its solo TILT-123 treatment. The firm, a pioneer in cancer immunotherapies, uses this oncolytic virus to activate T-cells, targeting patients with progressive solid tumors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.